On Thursday 25 September, the European Commission announced that it had granted marketing authorisation for Kisunla (donanemab), a drug designed to treat mild cognitive impairment, including mild dementia in the early stages of Alzheimer’s disease.
Kisunla was developed by the pharmaceutical company Eli Lilly and Company. Kisunla is a monoclonal antibody administered by intravenous infusion.
According to the Commission, Kisunla may help to “slow down the progression of cognitive and...